ResMed Inc. (RMD) Stake Increased by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ raised its position in shares of ResMed Inc. (NYSE:RMD) by 19.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,380 shares of the medical equipment provider’s stock after buying an additional 3,700 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in ResMed were worth $1,722,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sawtooth Solutions LLC increased its holdings in shares of ResMed by 1.6% during the second quarter. Sawtooth Solutions LLC now owns 3,167 shares of the medical equipment provider’s stock worth $247,000 after buying an additional 49 shares in the last quarter. YorkBridge Wealth Partners LLC increased its holdings in shares of ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 69 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of ResMed by 2.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,489 shares of the medical equipment provider’s stock valued at $272,000 after purchasing an additional 82 shares in the last quarter. Toronto Dominion Bank increased its holdings in shares of ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 197 shares in the last quarter. Finally, Utah Retirement Systems increased its holdings in shares of ResMed by 0.8% in the second quarter. Utah Retirement Systems now owns 25,583 shares of the medical equipment provider’s stock valued at $1,992,000 after purchasing an additional 200 shares in the last quarter. 62.02% of the stock is owned by institutional investors.

A number of analysts recently weighed in on RMD shares. Northland Securities reissued a “sell” rating and issued a $55.00 price target on shares of ResMed in a report on Friday, October 27th. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a report on Monday, October 30th. Barclays raised their price target on shares of ResMed from $65.00 to $68.00 and gave the company an “underweight” rating in a report on Monday, September 25th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a report on Friday, October 27th. Finally, J P Morgan Chase & Co raised their price target on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. ResMed presently has a consensus rating of “Hold” and a consensus target price of $67.57.

In other news, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction on Friday, December 1st. The shares were sold at an average price of $85.36, for a total transaction of $106,700.00. Following the transaction, the chief financial officer now directly owns 79,572 shares of the company’s stock, valued at $6,792,265.92. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Pendarvis sold 2,804 shares of ResMed stock in a transaction on Monday, December 4th. The stock was sold at an average price of $84.17, for a total transaction of $236,012.68. Following the transaction, the insider now directly owns 97,257 shares in the company, valued at $8,186,121.69. The disclosure for this sale can be found here. Insiders have sold a total of 184,693 shares of company stock valued at $15,149,955 in the last ninety days. Company insiders own 1.77% of the company’s stock.

ResMed Inc. (RMD) traded up $0.83 on Thursday, reaching $85.18. 444,500 shares of the company’s stock were exchanged, compared to its average volume of 853,212. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. ResMed Inc. has a 12-month low of $58.71 and a 12-month high of $87.81. The firm has a market cap of $11,969.59, a price-to-earnings ratio of 29.39, a PEG ratio of 1.87 and a beta of 0.78.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The firm had revenue of $523.66 million during the quarter, compared to analyst estimates of $506.08 million. During the same quarter in the previous year, the business earned $0.62 EPS. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. equities analysts forecast that ResMed Inc. will post 3 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be issued a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date is Wednesday, November 8th. ResMed’s dividend payout ratio is presently 56.68%.

TRADEMARK VIOLATION NOTICE: “ResMed Inc. (RMD) Stake Increased by Skandinaviska Enskilda Banken AB publ” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/resmed-inc-rmd-stake-increased-by-skandinaviska-enskilda-banken-ab-publ.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply